CClinicalTrials.gg
RecruitingNCT07866625Updated Oct 8, 2026

An Investigation of The Relationship Between Muscle Mass, Physiological Parameters, and Blood Gas Levels in Adult Patients Hospitalized in The Intensive Care Unit

An observational study in Intensive Care (ICU), sponsored by Ankara Yildirim Beyazıt University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Hours and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Ankara Yildirim Beyazıt University · Observational

From the registry’s dates

  • Started Dec 2025; still recruiting 9 months later.
Updated Oct 8, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
80
Ages
18 Hours and older
Sex
All
01

Study summary

This study was designed to investigate the relationship between muscle mass and physiological parameters and blood gas values in adult patients admitted to the intensive care unit. While muscle mass will be determined using anthropometric measurements, SpO₂, pulse rate, blood pressure, diuresis, and arterial blood gas values will be evaluated. The primary hypothesis of the study is that there is a significant relationship between muscle mass and, in particular, oxygenation and other physiological and blood gas parameters.

Read the detailed description

Intensive care units are facilities where patients whose physiological balance has been disrupted due to life-threatening illnesses are monitored and treated. In these patients, critical illness disrupts homeostasis, affecting multiple organ functions; sepsis, prolonged mechanical ventilation, and immobilization are significant risk factors for ICU-acquired weakness . These conditions lead to a loss of muscle mass, which negatively affects metabolic reserve, respiratory muscle strength, and recovery capacity; prolongs the length of hospital stay; and increases the risk of mortality.

Muscle tissue not only enables movement but also plays a critical role in metabolic and systemic regulation through the secretion of myokines. Therefore, muscle loss is not limited to physical weakness but also affects metabolic and systemic functions .Muscle weakness is common in intensive care patients, and losses exceeding 10%-particularly in the first few weeks-are associated with functional impairments .

A decrease in muscle mass can weaken respiratory muscle strength, leading to reduced oxygen saturation, impaired circulatory function, and decreased organ perfusion; this may manifest as pulse variability, low oxygen saturation, and decreased urine output. In a study of patients intubated due to COVID-19-related pneumonia, it was observed that individuals with high muscle density had higher extubation success rates, lower complication rates, and reduced mortality. Similarly, post-discharge measurement of quadriceps muscle mass using BIA showed a positive correlation with long-term recovery.The relationship between muscle mass and respiratory function was examined using DXA, and significant associations were found between restrictive ventilatory dysfunction and muscle mass . These data indicate that muscle mass indirectly supports oxygenation and hemodynamic stability.

The risk of muscle loss increases with prolonged immobilization, mechanical ventilation, and the use of high doses of sedatives. For this reason, the assessment of muscle mass in intensive care patients is important both for monitoring clinical course and for investigating its relationship with physiological parameters such as SpO₂, blood pressure, pulse, diuresis, and blood gas values.

Following a review of the literature, no study was found that examined the relationship between anthropometric measurements of muscle mass and physiological parameters and blood gas values in adult patients admitted to the intensive care unit. In this context, the study was planned.

Type of Study: Observational Study Study Population: Patients admitted to the palliative care intensive care unit, pulmonary intensive care unit, and cardiovascular intensive care unit at Erzurum City Hospital will be included in the study.

Sample Size: In this study, as the primary analysis, the relationship between muscle mass and SpO₂ will be evaluated using a one-way Pearson correlation; similar studies in the literature have shown a moderate correlation (r ≈ 0.30) (Damanti et al., 2022; Lim et al., 2024).Under these assumptions, a power analysis conducted with a statistical power of (1-β) = 0.80 and a significance level of (α = 0.05) determined that a sample size of approximately 67 patients would be required to test the hypothesis that SpO₂ values increase as muscle mass increases. To account for potential data losses, the sample size was planned to be approximately 80 patients.

The criteria used in similar studies in the literature that examine the relationship between muscle mass, muscle strength, and clinical outcomes in intensive care patients will serve as the basis.

Collection of research data: The research data will include adult patients hospitalized in the palliative care, pulmonary, and cardiovascular surgery intensive care units at Erzurum City Hospital. Informed consent forms will be obtained from the patients or their first-degree relatives, as well as from the attending physician in the intensive care unit.

Edema Assessment: This is a routine measurement. It poses no risk to human health. Before measurements begin, patients' upper and lower extremities will be assessed for edema. The assessment will be based on the pitting edema test-performed by applying light pressure with the thumb for 2-3 seconds-and clinical observation. For edema assessment, measurements will be taken at the widest point on the medial surface of the calf, the anterior aspect of the thigh, the midpoint of the femur (midpoint of the SIAS and the patella), the anterior surface of the midpoint of the humerus (between the acromion and the olecranon), and the posterior surface of the midpoint of the humerus (between the acromion and the olecranon).

For grading: 0+: No indentation → No edema; 1+: Mild indentation, recovers quickly → Mild edema, 2+: Moderate indentation, persists for a few seconds → Moderate edema, 3+: Deep indentation, persists for up to 15 seconds → Severe edema, 4+: Very deep indentation, persists for >30 seconds → Very severe edema; these values will be used.

Anthropometric Measurements Patients' circumference measurements and skinfold measurements will be taken while they are lying on their backs. Muscles will be kept relaxed, and a non-elastic anthropometric tape and a Baseline brand skinfold caliper will be used. Measurements will be taken on the right side of the body whenever possible; if access is obstructed, the left or opposite side will be used, and this will be noted on the record form. All measurements will be taken in a single attempt and recorded with a precision of 0.1 mm. The researchers performing the measurements have received training in accordance with the ISAK protocol.

Circumference Measurements: Measurements will be taken at the calf, thigh, and biceps. For the calf, measurements will be taken at the widest point of the calf ; for the thigh, at the midpoint of the femur on the anterior aspect of the thigh and 10 cm above the patella; and for the biceps, from the midpoint of the humerus , and the results will be recorded in centimeters.

Skinfold Measurements: Measurements will be taken from the biceps, triceps, suprailiac region, abdomen, thigh, and calf. Biceps: measured vertically from the midpoint of the humerus; triceps: measured vertically from the midpoint between the acromion and the olecranon; suprailiac: measured obliquely just above the iliac crest; abdomen: measured vertically 2 cm to the right of the navel; thigh: measured vertically from the midpoint of the femur; calf: vertically from the widest point of the calf, and the measurements will be recorded in centimeters.

Measurements will not be taken from the subscapular region, as it is believed this would interfere with patient positioning.

Muscle Mass Calculation: The thigh cross-sectional area formula will be used to calculate muscle mass.

The muscle radius (r) will be determined using the formula: thigh circumference / 2.

Then, using π = 3.14, the formula for muscle cross-sectional area = π (r - (skinfold thickness / 2))² will be used.

Physiological Parameters and Blood Gases: On the day anthropometric measurements are taken, patients' SpO₂, pulse rate, blood pressure, and diuresis will be recorded.

In addition, arterial blood gas (ABG) values will be based on data obtained during routine clinical follow-up within ±12 hours of the measurement time; no additional blood samples will be drawn. Parameters to be recorded: pH, PaO₂, PaCO₂, SaO₂, HCO₃-, base excess (BE), lactate, as well as FiO₂ and ventilator parameters.

Measurement of diuresis: For patients with a urinary catheter: The urine volume collected in the urine bag over a 12-hour period or ±12 hours will be recorded. For patients without a urinary catheter: Urine output by the patient over a 12-hour period (using a soft catheter or urine bag) will be recorded. Unit: To be recorded as mL/12 hours.

All data will be used to evaluate the relationship between muscle mass and oxygen saturation, blood pressure, pulse, diuresis, and blood gas parameters in intensive care patients.

Statistical Analysis: The data obtained from this study will be analyzed using SPSS (The Statistical Package for the Social Sciences). The Shapiro-Wilk test will be used to determine whether the data are normally distributed. The Pearson test will be used for groups with a normal distribution, and the Spearman test will be used for groups without a normal distribution. Results will be evaluated at a significance level of 0.05.

.

02

Conditions studied

  • Intensive Care (ICU)

Keywords

  • Intensive Care
  • Muscle Mass
  • Anthropometric measurements
  • arterial kan gaze
  • Oxygen Saturation
03

In context

Lead sponsor

Ankara Yildirim Beyazıt University is the lead sponsor of 229 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Hours and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study data will include adult patients hospitalized in the palliative care intensive care unit, the pulmonary intensive care unit, and the cardiovascular surgery intensive care unit at Erzurum City Hospital.

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:

Age: Adult patients aged 18 years and older Clinical unit: Patients admitted to palliative care, pulmonary intensive care, or cardiovascular intensive care units Length of stay: Patients expected to remain in the intensive care unit for at least 48 hours Physical eligibility: Patients with no conditions preventing the measurement of muscle mass Clinical stability: Patients without severe hemodynamic instability or active bleeding at the time of measurement Ethical compliance: Individuals who have volunteered to participate in the study and whose informed consent has been obtained from them or their legal representative

Exclusion Criteria:

  • Exclusion Criteria:

    • Patients with a history of previously diagnosed neuromuscular disorders (myasthenia gravis, Guillain-Barré syndrome, chronic polyneuropathies)
    • Patients with severe renal or hepatic insufficiency that could directly affect muscle mass
    • Presence of severe edema: Patients with a pitting edema score of 3+ or 4+ on the pitting edema test, or individuals with documented widespread edema in nursing or medical records
    • Patients with an amputation, hematoma, or open wound on the extremity to be measured
    • Pregnant patients
    • Patients whose intensive care stay lasted less than 48 hours or for whom the measurement could not be completed due to discharge or death
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • patients in intensive care

    patients in intensive care

06

What researchers measure

Primary outcomes

  1. muscle mass

    Time frame: 10.12.2026

07

Study locations

1 of 1 sites recruiting
  • Erzurum City Hospital,
    Erzurum, Turkey (Türkiye)
    • Sümeyye Karabacak · Sub investigator
    Recruiting
08

References and documents

Publications

  • Damanti S, Cristel G, Ramirez GA, Bozzolo EP, Da Prat V, Gobbi A, Centurioni C, Di Gaeta E, Del Prete A, Calabro MG, Calvi MR, Borghi G, Zangrillo A, De Cobelli F, Landoni G, Tresoldi M. Influence of reduced muscle mass and quality on ventilator weaning and complications during intensive care unit stay in COVID-19 patients. Clin Nutr. 2022 Dec;41(12):2965-2972. doi: 10.1016/j.clnu.2021.08.004. Epub 2021 Aug 16. PubMed 34465493 ↗
  • Brodovicz KG, McNaughton K, Uemura N, Meininger G, Girman CJ, Yale SH. Reliability and feasibility of methods to quantitatively assess peripheral edema. Clin Med Res. 2009 Jun;7(1-2):21-31. doi: 10.3121/cmr.2009.819. Epub 2009 Feb 26. PubMed 19251582 ↗
  • Fazzini B, Markl T, Costas C, Blobner M, Schaller SJ, Prowle J, Puthucheary Z, Wackerhage H. The rate and assessment of muscle wasting during critical illness: a systematic review and meta-analysis. Crit Care. 2023 Jan 3;27(1):2. doi: 10.1186/s13054-022-04253-0. PubMed 36597123 ↗

Individual participant data

Plan to share: Yes — all patient data

Supporting information: Sap

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866625
Lead sponsor
Ankara Yildirim Beyazıt University
Responsible party
Bihter Aslanyurek (Doç. Dr., Ankara Yildirim Beyazıt University) — Principal investigator
First posted
Oct 8, 2026
Start date
Dec 10, 2025
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 10, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Bihter Akınoğlu
Contact
RGKARDELEN@yahoo.com
+905059384136
Bihter AKINOĞLU
principal investigator · Ankara Yildiirm Beyazit University
Sümeyye Karabacak
study chair · Erzurum City Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion